CervoMed reports no difference between neflamapimod and placebo in DLB trial; OLE data expected Q1 2025

CervoMed Inc.

No discernible differences between neflamapimod 40mg TID and placebo during 16-week double-blind phase of RewinD-LB trial.
Measured trough plasma concentrations similar to 40mg BID in prior Alzheimer's study, lower than targeted.
Retrospective analysis suggests lower bioavailability related to age of drug batch used in double-blind phase.
PK data from food-effect study and within-subject comparison (13 participants) indicate newer capsules achieved target concentrations.
Topline data from first 16 weeks of open-label extension (OLE) phase expected in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.